- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Siemens debuts tissue harmonic imaging
Siemens Ultrasound of Issaquah, WA, has become the latest ultrasound vendor to add tissue harmonic imaging capabilities to its product line. The firm's version, called Ensemble Tissue Harmonic Imaging, will be offered on its premium Sonoline Elegra
Siemens Ultrasound of Issaquah, WA, has become the latest ultrasound vendor to add tissue harmonic imaging capabilities to its product line. The firm's version, called Ensemble Tissue Harmonic Imaging, will be offered on its premium Sonoline Elegra ultrasound scanners.
The new release allows Elegra users to isolate harmonic signal data without the use of contrast agents, according to the firm. Ensemble supports high-frequency imaging and can provide demonstration of breast lesions and superficial images. The system also shows promise in scanning difficult-to-image patients.
Ensemble eliminates the impact of signal artifacts common during high-frequency scanning with its pulse-inversion technology, which isolates harmonic imaging signals, according to Siemens. Combining the harmonic imaging signals with fundamental signal data allows Elegra to yield improvements in tissue contrast and spatial resolution in nearly all radiological applications, the company believes.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
